Citations

Institution: Mayo Clinic Clear

Showing 10 of 108119 citations.

Impact of hydrocortisone vs prednisone therapy on postsurgical recovery in patients with endogenous hypercortisolism: a prospective cohort study
Sandooja, Rashi , Saini, Jasmine , Taveras, Elio Ferreira, Gregg-Garcia, Raul, Zhang, Catherine D , Fell, Vanessa , Peersen, Anina, Achenbach, Sara J., Atkinson, Elizabeth J. , Garcia, Raul Gregg , Ferreira Taveras, Elio, Bancos, Irina , Saini, Jasmine , Garcia, Raul G , Gompel, Jamie J. Van , Young, William F. , Bancos, Irina

European Journal of Endocrinology | May 3, 2025 | Volume: 192 | Issue: 5 | Pages: 621-630

10.1093/ejendo/lvaf092 | PMID 40317190 Get It

Abstract Objective Glucocorticoid withdrawal syndrome (GWS) may develop in patients following successful surgery for endogenous hypercortisolism. Effective strategies to minimize GWS and improve quality of life (QoL) are currently lacking. We aimed to determine the impact of hydrocortisone vs prednisone therapy on GWS and QoL during the first 12 weeks postsurgery. Methods Single-center prospective cohort study (2019-2024) of adults with endogenous hypercortisolism who developed postoperative adrenal insufficiency and treated with either prednisone or hydrocortisone. Quality of life was assessed with Short Form-36 (SF-36) and Cushing QoL questionnaires at baseline and at 12 weeks postsurgery. GWS was assessed using weekly AddiQoL questionnaires for the first 12 weeks postsurgery. Results Of 165 patients, 101 (61%) were treated with hydrocortisone and 64 (39%) with prednisone. At baseline, no group differences were found in the hypercortisolism subtype, comorbidities, or QoL assessments. At follow-up, no group differences in final total daily hydrocortisone equivalent dose were seen. When adjusting for the baseline QoL assessment, patients treated with prednisone demonstrated a higher degree of improvement in their QoL, particularly in the SF-36 mental component score (estimate 0.33, 95% CI, 0.04-0.63), SF-36 role-emotional limitation (estimate 0.52, 95% CI, 0.2-0.84), and SF-36 body pain (estimate 0.31, 95% CI, 0.07-0.56) subcomponents. In the multivariable analysis of age, sex, body mass index, glucocorticoid type, baseline clinical severity score, and baseline QoL assessment, prednisone therapy was an independent predictor of better SF-36 mental component at 12 weeks postsurgery. Conclusions Prednisone therapy was associated with better mental health QoL than hydrocortisone at 12 weeks postsurgery in patients with hypercortisolism.
Spontaneous Thoracic Epidural Hematoma Results in Sensation and Motor Loss: A Case Report
LeBorgne, Melissa Holden, Abbas, Rawad , Parker, Jonathon J. , Martini, Wayne A , Ghaith, Summer

No container title available | May 3, 2025 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.22541/au.174627363.39161878/v1 Get It

Deucravacitinib in patients with inflammatory bowel disease: 12-week efficacy and safety results from 3 randomized phase 2 studies in Crohn’s disease and ulcerative colitis
D’Haens, Geert , Panaccione, Remo , Matsuoka, Katsuyoshi , Loftus, Edward V. , Kobayashi, Taku , Elsharkawi, Walid, Miceli, Rosa, Ahmed, Samia A. , Napoli, Andrew, Vaile, John, Dornic, Quentin, Patel, Aditya , Danese, Silvio , Panaccione, Remo , Kobayashi, Taku , Schreiber, Stefan , Loftus, Edward V , Danese, Silvio , Rubin, David T. , Peyrin‐Biroulet, Laurent , Luo, Yi , Matsuoka, K

Journal of Crohn's and Colitis | May 3, 2025 | Volume: 19 | Issue: 6 | Pages: No page available

10.1093/ecco-jcc/jjaf080 | PMID 40355364 Get It

Abstract Background and Aims Tyrosine kinase 2 is a downstream intracellular mediator of interleukin-23 signaling, which has a key role in the pathogenesis of inflammatory bowel disease. Deucravacitinib is a novel, oral, selective, allosteric tyrosine kinase 2 inhibitor currently approved for the treatment of adults with moderate to severe plaque psoriasis. Methods Here we describe 3 randomized, double-blind, placebo-controlled phase 2 studies of deucravacitinib in patients with moderately to severely active Crohn’s disease (LATTICE-CD [NCT03599622]) or ulcerative colitis (LATTICE-UC [NCT03934216] and IM011-127 [NCT04613518]). Patients were randomized to receive placebo or twice-daily deucravacitinib 3 or 6 mg (LATTICE-CD), 6 mg (LATTICE-UC), or 12 mg (IM011-127) for 12 weeks. Coprimary endpoints for LATTICE-CD were clinical remission and endoscopic response at week 12. The primary endpoint was clinical remission (per modified Mayo score) at week 12 for LATTICE-UC and clinical response (per modified Mayo score) at week 12 for IM011-127. Results A total of 239 (LATTICE-CD), 131 (LATTICE-UC), and 38 (IM011-127) patients were randomized. The primary endpoints were not met for all 3 studies, which resulted in early study termination for LATTICE-CD and IM011-127. High efficacy rates were observed in placebo groups throughout the studies. In all studies, the safety profile of deucravacitinib was consistent with the known safety profile observed in patients with psoriasis, and no new safety signals were observed. Conclusions Deucravacitinib at multiple doses did not demonstrate significant clinical benefit vs placebo in moderately to severely active Crohn’s disease or ulcerative colitis. Deucravacitinib was safe and well tolerated.
Intraoperative analysis of lymph nutrient vessels of 104 human lymph vessels using video‐capillaroscopy
Matsui, Chihiro , Tsukuura, Reiko, Sakai, Hayahito , Miyazaki, Toko , Tsukuura, Reiko , Escandón, Joseph M. , Mortada, Hatan Hisham , Yamamoto, Takumi

Wound Repair and Regeneration | May 3, 2025 | Volume: 33 | Issue: 3 | Pages: No page available

10.1111/wrr.70030 | PMID 40318094 Get It

Abstract The vasa vasorum of the superficial collecting lymph vessel (VCL) has been reported to show morphological changes in lymphedematous limbs. This study aimed to develop a pathophysiological severity staging of the superficial collecting lymph vessels (SCLs) based on VCL morphology. A retrospective review was conducted using the medical charts of lower extremity lymphedema patients who underwent video‐capillaroscopy (VC) during lymphaticovenular anastomosis (LVA). Intraoperative SCLs were evaluated using VC at 175× and 620× magnifications. The VCL stage was determined based on VCL morphology observed under VC. D2‐40 (podoplanin) staining was assessed with a score of 0 for negative, 1 for mildly positive, and 2 for strongly positive. Red blood cell (RBC) movement was scored as 1 for movement and 0 for no movement. A total of 32 patients with 104 SCLs were evaluated. The distribution of VCL stages was as follows: Stage 0 in 4 SCLs (3.8%), Stage 1 in 16 SCLs (15.4%), Stage 2 in 18 SCLs (17.3%), Stage 3 in 36 SCLs (34.6%), Stage 4 in 20 SCLs (19.2%), and Stage 5 in 10 SCLs (9.6%). A significant difference was observed in the prevalence of lymphosclerosis grade according to the VCL stage ( p = 0.002). Among the VCL stages (Stage 1 vs. 2 vs. 3 vs. 4 vs. 5), a higher VCL stage was significantly associated with lower positivity to D2‐40 staining of the SCL ( p < 0.001), as well as with lower positivity to RBC movement in both the main VCL ( p < 0.001) and the branch VCL ( p < 0.001). These findings indicate that the progression of the VCL stage is associated with pathologic changes in the SCLs and physiological deterioration of the VCLs, highlighting the significance of the VCLs in the progression of lymphedema.
Blood pressure variability and cardiovascular risk assessment using machine learning clustering after arteriovenous fistula creation in hemodialysis patients
Montoya, Christopher , Rix, Daniel Del Castillo, Polanía-Sandoval, Camilo , Dejman, Adriana, Vázquez-Padrón, Roberto I. , Tabbara, Marwan , Salman, Loay , Duque, Juan C. , Vazquez-Padron, Roberto I , Loay, Salman , Duque, Juan C , Polania-Sandoval, Camilo A , Martinez, Laisel , Dejman, Adriana, Reyes, Danna Lesley Cruz

The Journal of Vascular Access | May 3, 2025 | Volume: 27 | Issue: 1 | Pages: 258-265

10.1177/11297298251326313 | PMID 40317209 Get It

Introduction: Hypertension (HTN) is highly prevalent among patients with chronic kidney disease (CKD) and end-stage kidney disease (ESKD), uncontrolled HTN as well as high blood pressure variability (BPV) can significantly impact cardiovascular health. This study aims to understand the impact of BPV in patients with ESKD following arteriovenous fistula (AVF) creation for hemodialysis, to better understand its association with age, sex, BMI, and cardiovascular risk. Methods: A retrospective analysis was conducted on 83 patients who underwent AVF creation between February 2019 and October 2020 at University of Miami Hospital. During 20 months, blood pressure measurements were collected from medical records at four different times during AVF access creation process, and BPV was quantified using machine learning clustering techniques. Results: The study identified three distinct clusters among the 83 patients with ESKD who underwent AVF creation. Cluster 1 ( n = 28) was characterized by high blood pressure variability, with a mean systolic blood pressure standard deviation of 16.2 mmHg. This cluster exhibited a significantly higher cardiovascular risk rate of 42.9% compared to Cluster 2 ( n = 30) and Cluster 3 ( n = 25), which had lower variability with mean systolic blood pressure standard deviations of 10.3 and 8.7 mmHg, respectively, and cardiovascular risk rates of 16.7% and 12.0%. Age, sex, and BMI did not differ significantly across the clusters. Conclusion: This study underscores the association between blood pressure variability and the increased risk of cardiovascular events, including myocardial infraction, stroke or heart failure in patients with ESKD undergoing AVF creation. Our findings highlight the critical need for vigilant monitoring of blood pressure fluctuations in this population and demonstrate how these variations are influenced by individual demographic factors. Further research is needed to develop targeted interventions to mitigate this risk.
Multiple robotic stapler firings to transect the rectum are not associated with anastomotic leakage
Cardelli, Stefano , Stocchi, Luca , Merchea, Amit , DeLeon, Michelle , Mishra, Nitin , Hancock, Kevin , DeLeon, Michelle F, Hancock, Kevin J , Colibaseanu, Dorin , Larson, David W.

Colorectal Disease | May 3, 2025 | Volume: 27 | Issue: 5 | Pages: No page available

10.1111/codi.70094 | PMID 40317590 Get It

AbstractAimThe relationship between the number of stapler firings (SFs) during robotic rectal transection and the risk of colorectal/coloanal anastomotic leakage (AL) is controversial. This study investigates whether the number of robotic SFs is associated with an increased risk of AL.MethodRetrospective review of adult patients who underwent robotic total mesorectal excision (TME) and partial mesorectal excision (PME) with double‐stapled colorectal or coloanal anastomosis for both benign and malignant colorectal diseases between 2015 and 2023 across three enterprise‐wide hospitals. Primary outcome: the effect of multiple SFs on postoperative AL rate among patients who underwent one, two, or three or more SFs. Secondary outcome: the effects of other potential risk factors on postoperative AL.ResultsOf 503 patients who underwent robotic colorectal resection with a double‐stapled anastomosis, 56 (11%) developed a postoperative AL. The number of SFs was not associated with the AL rate (p = 0.51): the univariable and multivariate analyses found no correlation between the AL rate and the increasing number of SFs required, compared with one SF as the reference (adjusted two SFs, OR = 1.1, 95% CI: 0.6–2.2, p = 0.77 vs. adjusted three or more SFs, OR = 0.98, 95% CI: 0.4–2.3, p = 0.96). On multivariate analysis, AL was strongly associated with male gender (OR = 2.5, 95% CI: 1.3–4.9, p = 0.005) and with TME versus PME (OR = 2.8, 95% CI: 1.5–5.5, p = 0.002).ConclusionThe number of robotic SFs for rectal transection is not correlated with postoperative AL.
Atypical Facial Onset Weakness in SOD1 ALS
Garret, Mark A. , Namiranian, Dina , Milone, Margherita , Varadhachary, Arun S., Ho, Doreen

Muscle & Nerve | May 3, 2025 | Volume: 72 | Issue: 3 | Pages: 520-522

10.1002/mus.28428 | PMID 40317507 Get It

Clinical phenotypes among patients with familial forms of Chiari malformation type 1
Mekbib, Kedous Y. , Allington, Garrett , Zhao, Shujuan, Fortes, Carla, Shohfi, John, Nelson‐Williams, Carol , Butler, William E. , Alper, Seth L. , Jackson, Eric M., Muñoz, William , Mehta, Neel H. , Fan, Baojian , DeSpenza, Tyrone , Kahle, Kristopher T.

Journal of Neurosurgery: Pediatrics | May 2, 2025 | Volume: 36 | Issue: 1 | Pages: 109-118

10.3171/2025.1.peds24187 | PMID 40315599 Get It

OBJECTIVE Chiari malformation type 1 (CM1) is the most common neurological disorder of the craniocervical junction. CM1 is characterized by cerebellar tonsillar herniation below the foramen magnum, causing CSF obstruction and neural compression. Patients with CM1 suffer from highly variable symptoms, progression, comorbidities, and outcomes, partly due to poor understanding of CM1 pathogenesis. In this paper, the authors present the only familial CM1 cohort study to statistically assess intrafamilial clinical phenotypes to date. METHODS Comprehensive medical, surgical, and family histories and neuroimaging were collected from families with multiple CM1-affected family members. Univariate analysis was performed for each symptom, comorbidity, or surgery to compare observed versus expected frequencies of affected patients with another CM1-affected family member with the same clinical characteristic. RESULTS Twenty-four new familial CM1 cases (totaling 57 patients with CM1) are presented. Intrafamilial similarities were identified for age of onset, symptoms such as headaches (p = 0.007) and neck pain (p = 0.018), neurological comorbidities such as syringomyelia (p = 0.003) and hydrocephalus (p = 0.0001), neurodevelopmental conditions such as dyslexia (p < 0.0001), and connective tissue disorders (CTDs) such as Ehlers-Danlos syndrome (p < 0.0001). CONCLUSIONS These results suggest that CM1 and its associated clinical phenotypes, including age of onset, clinical symptoms, neurological comorbidities, neurodevelopmental conditions, and CTDs, are genetically influenced. Whole-exome sequencing of CM1 patient-parent trios has the potential to identify the genetic determinants of CM1, with implications for neurosurgical management.
Performance of Two-Phase Designs for the Time-to-Event Outcome and a Case Study Assessing the Relapse Risk Associated With B-ALL Subtypes
Chen, Wenan , Chang, Ti‐Cheng , Rabin, Karen R. , Raetz, Elizabeth A. , Devidas, Meenakshi , Hunger, Stephen P. , Ramirez, Nilsa C. , Mullighan, Charles G. , Loh, Mignon L. , Wu, Gang , Mullighan, Charles G , Hunger, Stephen P , Loh, Mignon L , Rabin, Karen R , Devidas, Meenakshi

JCO Clinical Cancer Informatics | May 2, 2025 | Volume: No volume available | Issue: 9 | Pages: No page available

10.1200/cci-24-00223 | PMID 40315406 Get It

PURPOSE To reduce costs in genomic studies of time-to-event phenotypes like survival, researchers often sequence a subset of samples from a larger cohort. This process usually involves two phases: first, collecting inexpensive variables from all samples, and second, selecting a subset for expensive measurements, for example, sequencing-based biomarkers. Common two-phase designs include nested case-control and case-cohort designs. Additional designs include sampling subjects based on follow-up time, like extreme case-control designs. Recently an optimal two-phase design using a maximum likelihood-based method was proposed, which could accommodate arbitrary sample selection in the second phase. However, direct comparisons of this optimal design with others in terms of power and computational cost is lacking. METHODS This study performs a direct evaluation of typical two-phase designs, including Tao's optimal design, on type I error, power, effect size estimation, and computational time, using both simulated and real data sets. RESULTS Results show that the optimal design had the highest power and accurate effect size estimation under the Cox regression model. Surprisingly, logistic regression achieved similar power with much lower computational cost than a more sophisticated method. The study further applied these methods to the MP2PRT study, reporting hazard ratios of cancer subtypes on relapse risk. CONCLUSION Recommendations for selecting two-phase designs and analysis methods are regarding power, bias of estimated effect size, and computational time.
Systemic Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer: ASCO Guideline Update
Garje, Rohan , Riaz, Irbaz Bin , Naqvi, Syed Arsalan Ahmed , Rumble, R. Bryan , Taplin, Mary‐Ellen , Kungel, Terry M. , Herchenhorn, Daniel , Zhang, Tian , Beckermann, Kathryn E. , Vapiwala, Neha , Celano, Paul , Hotte, Sebastién J. , Borno, Hala T. , Bryce, Alan H. , Wulff‐Burchfield, Elizabeth , He, Huan, Williams, J.E. Caerwyn , Hotte, Sebastien J , Basu, Arnab , Borno, Hala , Bryce, Alan H , Wulff-Burchfield, Elizabeth , Bodei, Lisa , Hamilton, Robert J , Emamekhoo, Hamid , Hope, Thomas A , Murad, M Hassan , Liu, Hongfang , Williams, James E , Parikh, Rahul A , Garje, Rohan , Herchenhorn, Daniel , He, Huan , Riaz, Irbaz B , Beckermann, Katy , Rumble, R Bryan , Carducci, Michael A. , Basu, Arnab , Wang, Peng , Bodei, Lisa , Loblaw, Andrew , Emamekhoo, Hamid , Hope, Thomas A. , Murad, M. Hassan , Liu, Hongfang

Journal of Clinical Oncology | May 2, 2025 | Volume: 43 | Issue: 20 | Pages: 2311-2334

10.1200/jco-25-00007 | PMID 40315400 Get It

ASCO Guidelines provide recommendations with comprehensive review and analyses of the relevant literature for each recommendation, following the guideline development process as outlined in the ASCO Guidelines Methodology Manual . ASCO Guidelines follow the ASCO Conflict of Interest Policy for Clinical Practice Guidelines . Clinical Practice Guidelines and other guidance (“Guidance”) provided by ASCO is not a comprehensive or definitive guide to treatment options. It is intended for voluntary use by clinicians and should be used in conjunction with independent professional judgment. Guidance may not be applicable to all patients, interventions, diseases or stages of diseases. Guidance is based on review and analysis of relevant literature, and is not intended as a statement of the standard of care. ASCO does not endorse third-party drugs, devices, services, or therapies and assumes no responsibility for any harm arising from or related to the use of this information. See complete disclaimer in Appendix 1 and 2 (online only) for more . PURPOSE To provide evidence-based recommendations for patients with metastatic castration-resistant prostate cancer (mCRPC). METHODS An Expert Panel including patient representation completed a systematic review of the evidence and made recommendations. RESULTS Depending upon prior treatment received, androgen receptor pathway inhibitors (ARPIs: enzalutamide, abiraterone with prednisone), poly(ADP-ribose) polymerase inhibitors (PARPi), chemotherapeutic agents (docetaxel, cabazitaxel), radiopharmaceuticals (radium 223, 177 Lu-prostate-specific membrane antigen [PSMA]-617), and sipuleucel-T have demonstrated an overall survival (OS) benefit for patients with mCRPC. For patients with BRCA1 / 2 alterations who did not receive prior ARPI, the combination of PARPi and ARPI (talazoparib + enzalutamide, olaparib and/or niraparib + abiraterone) has shown clinical benefit. For patients with BRCA1 / 2 alterations who received prior ARPI or ARPI followed by docetaxel, olaparib showed OS benefit. In select patients with microsatellite instability-high/mismatch repair-deficient, pembrolizumab showed clinical efficacy. RECOMMENDATIONS Prior systemic therapy for castration-sensitive prostate cancer will determine subsequent therapy used for mCRPC. Continue androgen-deprivation therapy for patients with mCRPC indefinitely. Early adoption of somatic genetic testing and palliative care is recommended. Patients with mCRPC and bony metastases should receive a bone-protective agent. The panel recommends the combination of ARPI with PARPi in patients with BRCA1 / 2 alterations who did not receive prior ARPI. For patients who received prior ARPI, the panel recommends docetaxel chemotherapy. The panel recommends 177 Lu-PSMA-617 or cabazitaxel chemotherapy for patients who receive prior ARPI and docetaxel chemotherapy. For patients with BRCA1 / 2 alterations who received prior ARPI, the panel recommends PARPi monotherapy. Radium 223 is recommended for patients with symptomatic bone–only disease. Evidence for optimal sequencing for mCRPC regimens is lacking. Additional information is available at www.asco.org/genitourinary-cancer-guidelines .